One of the IBAL modes of action targets cancer cells by apoptosis. Clinical studies on several human cancer cell types have used the cell’s natural death mechanism as an anticancer therapy. Treating the biological system to enhance apoptosis’s natural function to prevent cancer is one of the main functions. Animal studies of IBAL exhibit anticancer activity by activating the apoptotic pathway.
Exploiting the natural mechanisms for cell death is a highly effective method of treatment. Drugs targeting apoptosis are some of the most successful non-surgical therapies. Some have proven efficacy in all cancer cells as apoptosis evasion is a cancer hallmark, but they come with the cost of high cytotoxicity. IBAL creates apoptotic signals in several forms, cationic metal delivery, Zn/Cu SOD, redox signaling, and reduction of free radicals. All MoAs contribute to change the tumor environment through death ligands of IBAL in the extrinsic pathways creating extracellular signals to induce apoptosis. As a secondary MoA in the intrinsic pathway, death-inducing signals produced by cytotoxic T cells from the immune system respond to damaged, infected, or mutated cells.
Cancer cells switch their metabolism to glycolysis to meet their energy requirements, known as the Warburg effect. One of the anticancer MoA’s of IBAL exploits the Warburg effect to push the cancer cell further into the cellular respiration process to create an apoptotic death.
Using the specific natural components (nutritional metals) in an IBAL compound lowers the toxicity levels seen in current drug treatments. Multiple administration methods and dosing levels provide:
A spectrum of safety profiles that target tumor environments.
Tumor areas in all age groups.
Concurrent treatments.
